Clinicopathologic Features and Immunohistochemical Markers | β1 Integrin- | β1 Integrin+ | P-value | |||
---|---|---|---|---|---|---|
n (151) | (%) | n (74) | (%) | |||
Age (years) | <50 | 65 | 43.0 | 27 | 36.5 | 0.213a |
>50 | 86 | 67.0 | 47 | 63.5 | ||
Menstrual Status | Pre-menopausal | 54 | 35.8 | 24 | 32.4 | 0.367a |
Post-menopausal | 97 | 64.2 | 50 | 67.6 | ||
Size (mm) | <20 | 49 | 32.5 | 19 | 25.7 | 0.442b |
20-50 | 55 | 36.4 | 33 | 44.6 | ||
>50 | 47 | 31.1 | 22 | 29.7 | ||
Tumoral Grade | I | 57 | 37.7 | 25 | 33.8 | 0.845b |
II | 71 | 47.0 | 37 | 50.0 | ||
III | 23 | 15.2 | 12 | 16.2 | ||
Lymph node Status | Negative | 75 | 49.7 | 33 | 44.6 | 0.283a |
Positive | 76 | 50.3 | 41 | 55.4 | ||
Clinical Stage | I | 22 | 14.6 | 10 | 13.5 | 0.677b |
II | 72 | 47.7 | 30 | 40.5 | ||
III | 49 | 32.5 | 30 | 40.5 | ||
IV | 8 | 5.3 | 4 | 5.4 | ||
Death | No | 116 | 76.8 | 40 | 54.1 | 0.001 a |
Yes | 35 | 23.2 | 34 | 45.9 | ||
Metastasis | No | 115 | 76.2 | 48 | 64.9 | 0.05 a |
Yes | 36 | 23.8 | 26 | 35.1 | ||
ER | Negative | 48 | 31.8 | 21 | 28.4 | 0.359a |
Positive | 103 | 68.2 | 53 | 71.6 | ||
PR | Negative | 64 | 42.4 | 33 | 44.6 | 0.431a |
Positive | 87 | 57.6 | 41 | 55.4 | ||
p53 | Negative | 114 | 75.5 | 51 | 68.9 | 0.187a |
Positive | 37 | 24.5 | 23 | 31.1 | ||
Ki-67 | Negative | 107 | 70.9 | 54 | 73.0 | 0.435a |
Positive | 44 | 29.1 | 20 | 27.0 | ||
HER2 | Negative | 126 | 83.4 | 52 | 70.3 | 0.019 a |
Positive | 25 | 16.6 | 22 | 29.7 | ||
VEGF | Negative | 114 | 75.5 | 66 | 89.2 | 0.011 a |
Positive | 37 | 24.5 | 8 | 10.8 |